PL-6983

Last updated
PL-6983
Clinical data
Routes of
administration 		Subcutaneous injection
Drug class Melanocortin MC4 receptor agonist
Identifiers
CAS Number
PubChem SID

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. [1] [2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. [1] [2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models. [1] [2] The drug has reportedly been in pre-clinical development for all medical indications since 2008. [3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983." [4] The chemical structure of PL-6983 has yet to be made public.

Contents

See also

References

  1. 1 2 3 Simon JA (July 2009). Mitchner N (ed.). "Opportunities for intervention in HSDD" (PDF). The Journal of Family Practice. 58 (7 Suppl Hypoactive): S26–30. PMID   19825316. Archived from the original (PDF) on 2015-05-18. Retrieved 2015-05-14.
  2. 1 2 3 Krychman ML, Finestone S (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN   978-1-4496-1936-7.
  3. ↑ "Research programme: sexual dysfunction therapy - Palatin Technologies". AdisInsight. Springer Nature Switzerland AG. Retrieved 2019-06-06.
  4. ↑ "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". 2015-05-26. Archived from the original on 2015-05-26.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.